• 2,500 women
    were determined to be at high risk for breast cancer by the High Risk Screening Program in Ontario in 2014
  • 84%
    of cancer patients saw a registered dietitian at a regional cancer centre within 14 days of referral in 2015
  • 72%
    of stage III colon cancer patients received chemotherapy within 60 days after surgery
  • 84%
    of all cancer surgery patients received their consult within the recommended wait time in 2015, and 88% received their surgery within the recommend wait time
  • 29%
    of patients with oropharynx cancer and 20% with cervical cancer visited the emergency department while undergoing a course of curative radiation therapy between 2012 and 2015
  • 44%
    of breast cancer patients, 48% of colon cancer patients and 62% of lymphoma patients visited the emergency department or were admitted to hospital at least once while receiving chemotherapy
  • About 25%
    of patients who undergo lung, prostate and colorectal surgery have an unplanned hospital visit following cancer surgery
  • 64%
    of cancer patients had a first consult with an outpatient palliative care team within 14 days of referral in 2015
  • 40%
    of cancer patients visited the emergency department in the last 2 weeks of life in 2012
  • 361,991
    unique patients were screened for symptom severity using ESAS in 2015, representing 60% of patients
Click here to emailClick here to printClick here to share



How does Ontario compare?

“Working together to create the best cancer system in the world” is Cancer Care Ontario’s vision. Is Ontario succeeding? To find out, national and international data were compared against Ontario’s results. The selected findings presented below identify where Ontario is doing well and where improvements are needed in relation to other jurisdictions.

A note on jurisdictional comparisons

  • This is the seventh year that the Cancer System Quality Index (CSQI) has showcased international comparators for Ontario’s performance.
  • Here Ontario is compared with selected jurisdictions, in most cases because they have healthcare and data systems that are similar to those in Ontario, and because the way they measure participation is similar to Ontario.
  • Ensuring there are comparable data and measures from multiple jurisdictions is a challenge. It is wise to be mindful of the different data definitions, methodologies and years that are used for indicators measured outside of Canada. The design and context of other organized screened programs may also be different than those in Ontario. Cross-jurisdictional comparison is still useful, however, for providing a rough indication of how well Ontario is doing compared to other jurisdictions.

What aspects of cancer are we comparing?